Rhythm is a biopharmaceutical company dedicated to changing how rare genetic disorders of obesity are diagnosed and treated. Disorders of severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key pathway responsible for regulating weight, that lead to excessive or insatiable hunger or hyperphagia. Rhythmâs MC4R agonist, setmelanotide, is being evaluated in multiple late-stage clinical studies. The company is also leading efforts to improve patient identification and diagnosis through genetic testing and deepen the communityâs understanding of the ongoing impact and burden of disease on patients and caregivers. Source
No articles found.
Sorrentoâs lead programs with short-term milestones consist of two clinical stag...
Sorrentoâs lead programs with short-term mile...
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on ap...
InflaRx (Nasdaq: IFRX) is a clinical-stage biop...
Eton Pharmaceuticals, Inc. is a Deer Park, IL-based biopharmaceutical company focu...
Eton Pharmaceuticals, Inc. is a Deer Park, IL-b...
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused ...
DiaMedica Therapeutics Inc. is a clinical stage...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet...
Theratechnologies (TSX: TH) is a specialty phar...
Join the National Investor Network and get the latest information with your interests in mind.